Spotlight on GEM103 – Restoring Physiologic Complement Activity with Complement Factor H (CFH) for GA

Time: 1:45 pm
day: Track 2 Day 1 PM 1


  • Examine how Complement Factor H (CFH) dysfunction is evident in the pathogenesis of dry AMD
  • Explore GEM103, a novel recombinant human CFH in clinical development for the treatment of dry AMD and
  • Examine phase 2a data showing intravitreal GEM103 dosing results in sustained supraphysiological CFH in aqueous humor with functionality confirmed through reduction in complement activation biomarkers
  • Explore how intravitreal GEM103 shows strong safety profile, well tolerated with minimal inflammation/CNV